Xeris Biopharma Hosts XP-8121 Program Webinar, Files 8-K

What Happened Xeris Biopharma Holdings, Inc. (XERS) filed a Form 8-K on September 9, 2026 to disclose a Regulation FD presentation: the company will host an "XP-8121 Program Overview" webinar on September 9, 2026. The slide presentation to be used by senior management is furnished as Exhibit 99.1 to the 8-K; a related press release dated September 9, 2026 is furnished as Exhibit 99.2. The filing is signed by Steven M. Pieper, Chief Financial Officer.

Key Details

• Event: XP-8121 Program Overview webinar scheduled for September 9, 2026.
• Exhibits: Investor presentation furnished as Exhibit 99.1; press release dated September 9, 2026 furnished as Exhibit 99.2.
• Filing: Current Report on Form 8-K filed September 9, 2026 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits).
• Authorized signature: Signed by CFO Steven M. Pieper.

Why It Matters This 8-K provides investors with management's slide presentation and a press release about the XP-8121 program, ensuring material information is shared publicly and evenly (Regulation FD). Retail investors should review the furnished presentation and press release for any program updates or timelines that could affect the company's clinical or development outlook.